Case study

Uncovering biological mechanisms through metabolomic analysis

The Challenge

MISAME‑III aims to evaluate a nutritional supplement for pregnant and lactating women and to understand the biology underlying fetal and infant health in rural Burkina Faso. The project involves multiple omics—including metabolomics, proteomics, metagenomics and methylomics—and requires sophisticated analysis to uncover mechanisms.

Our Approach

We integrated diverse omics data, adjusted for confounders and uncovered mechanisms of supplementation with advanced analyses and visualisations.

  • Multi‑omics integration & confounder adjustment: Collected and annotated omics datasets, assessed statistical significance with FDR correction and built a pipeline to remove confounder effects and correlate within and across omics.
  • Mechanism discovery & visualisation: Identified biological mechanisms and microbial pathways through enrichment and causal mediation analyses, and produced publication‑quality visualisations using an expert team.

The Outcome

  • Developed a flexible analytics pipeline applicable to multiple omic types.
  • Extracted valuable information on mechanisms underpinning maternal and infant health.
  • Identified concerted microbial pathways and produced high‑quality visualisations.
  • Work contributed to a series of publications in peer‑reviewed journals.

Why It Matters

Multi‑omics integration can reveal complex biological mechanisms that single‑omic analyses miss. This project provides a reusable framework for nutrition and health studies and demonstrates the power of combining machine learning, statistics and domain expertise.

Let’s discuss how we can turn your data into real scientific impact.

Contact us >

Beyond animal testing in drug development

Beyond animal testing in drug development

For over a century, the life sciences industry has relied on animal models as the standard for predicting drug safety and effect. But today, the industry faces a harsh reality: over 90% of new drugs that appear safe and effective in animal tests ultimately fail in human clinical trials (see for example Ineichen et al. 2024 [1] and Marshall et al. 2023[2])

How spatial biology improves clinical trial success in oncology

How spatial biology improves clinical trial success in oncology

Oncology drug development often begins in patients, allowing early safety and efficacy insights. Yet many cancer drugs still fail in the clinic. We validate the target but ignore its context within the tumor microenvironment. This article explores why spatial biology may improve clinical success.